中国药学杂志 Chinese Pharmaceutical Journal
ISSN 1001-2494 CN 11-2162/R

中国药学杂志 » 2013, Vol. 48 » Issue (3) :230-233 DOI: 10.11669/cpj.2013.03.017

新型血小板聚集抑制剂研究进展

姜攀

广西百色市中医医院药剂科，广西 百色 533000

摘要 目的 血小板的激活和聚集在心血管疾病形成过程中起到核心作用，大量临床试验表明口服抗血小板药物，在有效性、患者耐受性及药物不良反应方面都存在一定不足，作用将以上诸方面内容及国内外对于新型血小板聚集抑制剂的研究进展做一综述。方法 参阅相关文献，对血小板聚集抑制剂的作用机制及临床试验研究现状和临床应用价值进行归纳和综述。结果与结论 一些新型血小板聚集抑制剂已经批准上市，另一些药物也已进入Ⅲ期临床试验。新型血小板聚集抑制剂有许多潜在优势，有利于急性冠脉综合征的防治。

关键词： 血小板聚集抑制剂；急性冠状动脉综合征 二磷酸腺苷P2Y12受体拮抗剂 经皮冠状动脉介入治疗 血栓素A2受体拮抗剂 凝血酶受体拮抗剂 磷酸二酯酶抑制剂 DZ-697b

Abstract：

Keywords：

收稿日期：2013-02-04；

作者简介：姜攀，男，主管药师 研究方向：医院药学 Tel：13517760677 E-mail：jiangpan5366@sina.com

引用本文：
姜攀 .新型血小板聚集抑制剂研究进展[J] 中国药学杂志, 2013,V48(3): 230-233

JIANG Pan .[J] Chinese Pharmaceutical Journal, 2013,V48(3): 230-233

[1] NBS. 2010 communique of the sixth national census data(No.1). 2011-04-28. http：//www.stats.gov.cn/tjfx/jdfx/t20110428_402722253.htm.

[2] ICH. Clinical Investigation of Medicinal Products in the Pediatric Population.2000-07-20. http：//www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Effic-acy/E11/Step4/E11_Guideline.pdf.

[3] DONG Y. Discussion on the safety of pediatric drugs. *Chin J Pharmaovigilance*(中国药物警戒)， 2009，6(7)：401-403.

[4] ICH. Dose-Response Information to Support Drug Registration. 1994-03-10. ht-tp：//www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E4/Step4/E4_Guideline.pdf.

[5] ICH. Ethnic Factors in the Acceptability of Foreign Clinical Data. 1998-02-05.http：//www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/St-ep4/E5_R1__Guideline.pdf.

[6] ICH. Good Clinical Practice. 1996-06-10. http：//www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf.

[7] ICH. Choice of Control Group and Related Issues in Clinical Trials. 2000-07-20. http：//www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf.

[8] ICH. Statistical Principles for Clinical Trials. 1998-02-05. http：//www.ich.org/fi-leadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf.

[9] SFDA. Good clinical practice. 2003-08-06. http：//www.sfda.gov.cn/WS01/CL/0053/24473.html.

[10] SFDA. The issuance of the notice of the guiding principles of vaccine clinical trials . 2004-12-03. http：//www.sfda.gov.cn/WS01/CL/0844/10307.html.

[11] SFDA. The issuance of the Guideline on Management of Phase I Clinical Trial of D-rugs (interim) . 2011-12-02. http：//www.sda.gov.cn/WS01/CL/0055/10307.html.

[12] CHEN Q， DU G， ZHANG D R. The status and progress of the children's drug use a-nd its clinical research. *Her Med* (医药导报)，2011，30(5)：593-597.

[13] BHATT D L，LINCOFF A M，GIBSON C M，*et al*. Intravenous platelet blockade with cangrelor during PCI.*N Engl J Med*，2009，361(24)：2330-2341.

[14] HARRINGTON R A， STONE G W，MCNULTY S，*et al*.Platelet inhibition with cangrelor in patients undergoing PCI.*N Engl J Med*，2009，361(24)：2318-2329.

[15] JAMES S， AKERBLOM A，CANNON C P，*et al*.Comparison of ticagrelor， the first reversible oral P2Y12 receptor antagonist， with clopidogrel in patients with acute coronary syndromes： Rationale， design， and baseline characteristics of the PLATelet inhibition and patient outcomes (PLATO) trial.*Am Heart J*，2009，157(4)：599-605.

[16] WALLENTIN L. P2Y12 inhibitors： Differences in properties and mechanism of action and potential consequences for clinical use . *Eur Heart J*， 2009， 30（16）：1964-1977.

[17] LIEU H D， CONLEY P B， ANDRE P， *et al*. Initial intravenous experience with PRT060128 (PRT128)， an orally-available， direct-acting，and reversible P2Y12 inhibitor. *J Thromb Haemost*， 2007，5(suppl 2)： P-T-292.

[18] LEONARDI S， RAO S V， HARRLINGTON R A， *et al*.Rationale and design of the randomized， double-blind trial testing INtraveNous and Oral administration of elinogrel， a selective and reversible P2Y12-receptor inhibitor， versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI).*Am Heart J*，2010，160(1)：65-72.

[19] Portola Pharmaceuticals. A Phase 2 Safety and Efficacy Study of PRT060128， a Novel Intravenous and Oral P2Y12 Inhibitor， in Non-Urgent PCI (INNOVATE-PCI) . http：//clinicaltrials.gov/ct2/ show/ NCT00- 751231.

[20] GURBEL P A，BLINDON K P，ANTONINO M J，*et al*.The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to cyp 2c19*2 genotype： First experience in patients. *J Thromb Haemost*， 2010，8（1）：43-53.

[21] BERGER J S， ROE M T， GIBSON C M， *et al*.Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel， a direct-acting and reversible P2Y12 ADP-receptor antagonist， before primary percutaneous intervention in patients with ST-elevation myocardial infarction： The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial .*Am Heart J*， 2009， 158(6)：998-1004.

[22] TIAN C H， SHEN L. The pediatric drug research and drug safety. *Chin J Pharmacovigilance*(中国药物警戒)， 2009，6(9)：518-521.

[23] SFDA. The accreditation review of clinical of drug clinical trial institution qualificatio-n(No.1).2012-02-29. http：//www.sda.gov.cn/WS01/CL/0069/69642.html.

[24] RAO S V.A randomized， double-blind， active controlled trial to evaluate intravenous and oral PRT060128 (elinogrel)， a selective and reversible P2Y12 receptor inhibitor vs clopidogrel as a novel antiplatelet therapy in patients undergoing nonurgent percutaneous coronary interventions. in Proceedings of the European Society of Cardiology Congress， Stockholm， Sweden， 2010.

[25] YANG L， LUO C， CHEN J. Pediatric exclusivity system(Ⅰ). *Chin New Drug J*(中国新药杂志)， 2009，18(8)：677-680.

[26] HIRSCHLER B.UPDATE 1-Novartis， Portola heart drug moves to final tests . Adds comment from doctors portolaceo，stockholm，Reuters，2008-08-30.

[27] YANG Z M， ZHANG P P. The current approval status and characteristic analysis of pediatric drugs overseas. *Chin Pharm J*(中国药学杂志)，2012，47(10)：745-748.

[28] DERIAN C K，DAMIANO B P， ADDO M F，*et al*.Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates.*J Pharmacol Exp Ther* ， 2003，304(2)：855-861 .

[29] CHACKALAMANNIL S，WANG Y，GREENLEE W J，*et al*.Discovery of a novel， orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. *J Med Chem*， 2008， 51（11）：3061-3064.

[30] BECKER R C， MOLITERNO D J， JENNINGS L K， *et al* .Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention： A randomized， double-blind， placebo-controlled phase II study.*Lancet* ，2009，373（9667）：919-928.

[31] GOTO S， YAMAGUCHI T， IKEDA Y， *et al* .Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. *J Atheroscler Thromb*， 2010，17(2)：156-164 .

[32] Schering-Plough .Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Acute Coronary Syndrome (TRA CER) (Study P04736AM3). http ：//clinicaltrials. gov /ct2/show/NCT00527943.

[33] Schering-Plough .Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2° P-TIMI 50) (Study P04737AM3).http：//clinicaltrials. gov/ ct2/show/NCT00526474.

[34] Eisai Inc. Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects with Acute Coronary Syndrome. http：// clinicaltrials. gov/ ct2/ show/NCT00548587.

[35] Eisai Inc .Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease. http：// clinicaltrials. gov/ ct2/ show/NCT00312052.

[36] O'DONOGHUE M L， BHATT D L， WIVIOTT S D， *et al* .Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes： The lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial.*Circulation*， 2011，123(17)：1843-1853.

[37] HENNERICI M G， BOTS M L， FORD I， *et al* .Rationale， design and population baseline characteristics of the PERFORM Vascular Project：An ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) trial.*Cardiovasc Drugs Ther*， 2010， 24(2)： 175-180.

[38] FIESSINGER J N， BOUNAMEAUX H， CAIROLS M A， *et al*. Thromboxane antagonism with terutroban in peripheral arterial disease： The TAIPAD study . *J Thromb Haemost*， 2010， 8(11)：2369-2376.

[39] Shinobara. The results of CSPS， a large-scale clinical trial of cilostazol in preventing recurrent stroke， presented at American Stroke Association′s International Conference. San Antonio， on February 26， 2010.

[40] ZAFAR M U， IBANEZ B， CHOL B G， *et al*. A new oral antiplatelet agent with potent antithrombotic properties： Comparison of DZ-697b with clopidogrel in a randomized phase Ⅰ study . *J Thromb Haemost*， 2010， 103(1)：205-212.